How to find and join an Alzheimer’s prevention trial

Here is something most carriers do not realize: the genotype that feels like a burden is, to researchers, valuable. Prevention trials actively seek out APOE4 carriers, especially people with no symptoms yet, because that is exactly who you need to test whether an intervention can change the trajectory before the disease takes hold. Joining one is a real, open option, and worth understanding even if you ultimately decide to pass.

This guide covers why a trial might be worth your time, where to actually find one (including registries that match you by APOE genotype), and the questions to ask before you sign anything.

Why a carrier might consider it

Three reasons come up most often, and they pull in different directions, so weigh the one that matters to you.

• Access to the frontier. A trial can put a promising intervention, careful monitoring, and real expert attention in front of you years before any of it reaches general use.
• Contributing to the answer. Prevention research simply cannot happen without participants, and carriers are who many of these studies are built around. Some are designed specifically by amyloid status or APOE genotype, which means you are not a generic volunteer; you are the point.
• Information about yourself. Some studies include cognitive assessments and biomarker measures as part of taking part, with proper consent and counseling.

Where to look

A few reputable starting points, roughly from broadest to most carrier-specific:

• ClinicalTrials.gov, the comprehensive U.S. government registry. Search by condition (for example “Alzheimer’s prevention”) plus your location, then filter for studies that are actively recruiting.
• The NIA’s clinical-trials resources, which curate Alzheimer’s and aging studies and explain how trials work in plain language.
• Alzheimer’s Association TrialMatch, a free service that connects people to studies they may be eligible for.
• Genotype-matched registries. GeneMatch, run by the Alzheimer’s Prevention Registry at Banner Alzheimer’s Institute for US adults aged 55 to 75, mails you a cheek swab, genotypes your APOE, and uses the result to match you to studies. It does not tell you your own genotype. It is built for precisely this audience.
• A carrier community. The peer-run APOE4.Info community is where many carriers first find each other and learn which studies are recruiting right now.

To make that concrete, the kinds of studies a healthy carrier might actually encounter include the AHEAD 3-45 study (testing lecanemab in cognitively normal people with intermediate or elevated amyloid) and the various World-Wide FINGERS lifestyle trials.

One distinction shapes your eligibility more than anything else: drug-prevention trials usually require biomarker confirmation to enroll (an amyloid PET, or a spinal-fluid or blood test), while lifestyle trials generally do not. So which door is open to you depends partly on which type you pursue.

What to know before you enroll

A trial is a serious commitment, and informed consent is the whole point, not a formality. Walk in with questions, and group them around the four things that actually determine whether it is right for you.

Purpose and design. Is there a placebo group, and what are your odds of landing in it? What are the real demands on your time, travel, and body (scans, lumbar punctures, infusions)?

Risks and how they are monitored. This is the heart of it for drug-prevention trials. Enrolling a healthy carrier in an anti-amyloid prevention study is a genuinely different risk calculus from treating someone who already has symptoms: the cognitive benefit is still unproven in prevention, while the ARIA risk (higher in carriers, highest in people with two copies) is the same either way. Ask exactly how that risk is handled for your specific genotype.

Whether you will learn your results. Some studies disclose your genotype or biomarker status, some do not. Decide in advance how you would handle either answer, ideally with a genetic counselor, before you are surprised by it.

What happens when it ends. Ask about continued access to the intervention, follow-up, and your right to withdraw at any time, for any reason.

Common questions

Do I have to already have symptoms to join? No, and this is the part people get backwards. Many prevention trials specifically want cognitively healthy people, often selected by risk factors like APOE genotype or amyloid status. Recruiting people before symptoms is the entire idea.

Will joining a trial tell me my genotype or whether I have amyloid? Sometimes. Policies vary, some disclose and some do not, so ask up front and decide in advance whether you actually want to know, with counseling support.

Is a trial a substitute for treatment? No. A trial is research, not a treatment plan, and it may involve a placebo. It also does not replace the everyday levers, which remain your foundation regardless of whether you enroll.

A trial is a personal decision, best made with your clinician and, where genetics are involved, a genetic counselor. But if contributing to the science appeals to you, the door is unusually open to carriers. That is a rare upside worth knowing about. This is general education, not medical advice.